Published in Health Business Week, May 5th, 2006
In connection with the initiation of phase 2 development, Vertex earned a $10 million milestone payment in March 2006 from Merck & Co., Inc. Vertex and Merck have a global collaboration to develop and commercialize VX-680.
The initiation of phase 2 development for VX-680 is based on the enrollment of patients with advanced colorectal cancer in a phase 2 extension of a previous phase 1 clinical study. In addition, Merck expects to initiate a phase 2 clinical study for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week